Mr. Borkowski is an experienced financial executive in the pharmaceutical industry. He served as Chairman and then Lead Independent Director, First Wave Biopharma (NASDSAQ:FWBI) 2015 to date. Prior, He served as Interim Chief Financial Officer, Executive Vice President of MiMedx Group (Nasdaq: MDGX) from 2018 until 2019.
Previously, he served as the Chief Financial Officer and Executive Vice President of Mylan N.V. (formerly MYSE:MYL) from 2002 until 2009, which was acquired by Pfizer (NYSE:PFE). Mr. Borkowski has also served as Chief Financial Officer of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral, controlled release products from 2013 until 2016.
In addition, Mr. Borkowski previously held the position of Chief Financial Officer with Convatec (LON:CTEC) from 2012 until 2013, a global medical device company focused on wound care and ostomy, and Carefusion (formerly NYSE:CFN) from 2009 until 2011, a global medical device company for which he helped lead its spin-out from Cardinal Health into an independent public company. Mr. Borkowski has been the Chief Financial Officer of Aceto Corporation (Nasdaq: ACET), and has held several executive positions with Concordia International, an international specialty pharmaceutical company from 2015 until 2017.
He has also served in senior financial positions at Pharmacia and American Home Products (Wyeth). He started his career with Arthur Andersen & Co. after receiving his MBA in accounting from Rutgers University subsequent to having earned his degree in Economics and Political Science from Allegheny College. Mr. Borkowski is currently a trustee and a member of the Executive Committee of Allegheny College.
